Method of diagnosing cancer and reagents therefor
The present invention provides methods for diagnosis and monitoring the efficacy of treatment of a cancer. More particularly, the methods of the invention comprise detecting an enhanced degree of chromatin modification within Chromosome 2 of the human genome from about map position 2q14.1 to about map position 2q14.3 in a sample derived from a subject. The methods include detecting an enhanced level of methylation, or detecting an enhanced level of modification of a histone positioned within the chromatin within the region of about 2q14.1 to 2q14.3 of Chromosome 2. The methods also include detecting a modulated level of expression of a gene within the region of about 2q14.1 to 2q14.3 of Chromosome 2. The gene may be selected from the group consisting of DEAD box polypeptide 18 (DDX18), translin (TSN), v-ral simian leukaemia viral oncogene homolog B (RALB), secretin recepto (SCTR), engrailed homolog 1 (EN1), macrophage receptor with collagenous structure (MARCO), protein tyrosine phosphatase non-receptor type 4 (PTPN4), insulin induced gene 2 (INSIG2), inhibin beta B (INHBB), GLI-Kruppel family member 2 (GLI2), FLJ10996, STEAP3, diazepam binding inhibitor (DBI), MGC10993, erythrocyte membrane protein band 4.1 like 5 (EPB41L5), FLJ14816, transcription factor CP2-like 1 (TFCP2L1).
1. A process for diagnosing a cancer, determining a prognosis for a subject suffering from a cancer or determining the efficacy of treatment of a cancer comprising:
(i) identifying and/or detecting enhanced methylation of a nucleic acid positioned within Chromosome 2 from about map position 2q14.1 to about map position 2q14.3 in a sample from a subject by performing a method comprising:
(a) treating the sample with an amount of a compound that selectively mutates a non-methylated cytosine residue under conditions sufficient to induce mutagenesis thereby producing a mutated nucleic acid;
(b) performing an amplification reaction with nucleic acid primers comprising a nucleotide sequence that is complementary to a sequence flanking or adjacent to a methylated cytosine residue or mutated residue at an equivalent position in non-methylated nucleic acid, wherein said methylated cytosine residue or said mutated residue is within a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 21 and SEQ ID NO: 25; and
(c) identifying and/or detecting the temperature at which the amplified nucleic acid produced at (b) denatures, wherein the temperature at which the nucleic acid denatures is indicative of the presence of a methylated cytosine residue or a mutated residue and the level of methylation of said nucleic acid; and
(ii) comparing the level of methylation of the nucleic acid at (i) to the degree of methylation in a non-cancerous cell, wherein an enhanced level methylation in the nucleic acid at (i) compared to the level of methylation in the non-cancerous cell is indicative of enhanced methylation in the sample from the subject and cancer or a predisposition therefor.
2. A process for diagnosing a cancer, determining a prognosis for a subject suffering from a cancer or determining the efficacy of treatment of a cancer comprising:
(i) identifying and/or detecting enhanced methylation of a nucleic acid positioned within Chromosome 2 from about map position 2q14.1 to about map position 2q14.3 in a sample from a subject by performing a method comprising:
(a) treating said sample with an amount of a compound that selectively mutates a non-methylated cytosine residue under conditions sufficient to induce mutagenesis thereby producing a mutated nucleic acid;
(b) performing an amplification reaction with nucleic acid primers comprising a nucleotide sequence that is complementary to a sequence flanking or adjacent to a methylated cytosine residue or mutated residue at an equivalent position in non-methylated nucleic acid, wherein at least one of said probes or primers comprises a region that selectively hybridizes to an amplicon comprising a nucleotide sequence complementary to the mutated residue produced in the amplification reaction thereby forming a hairpin nucleic acid and preventing further amplification of said nucleic acid, and wherein said methylated cytosine residue or said mutated residue is within a nucleic acid comprising a nucleotide sequence set forth in SEQ ID NO: 11 or SEQ ID NO: 21; and
(c) identifying and/or detecting the amplified nucleic acid, wherein the detection of said amplified nucleic acid is indicative of the presence of a methylated cytosine residue or a mutated residue and the level of methylation of said nucleic acid; and
(ii) comparing the level of methylation of the nucleic acid at (i) to the level of methylation in a non-cancerous sample, wherein an enhanced level of methylation in the nucleic acid at (i) compared to the level of methylation in the non-cancerous sample is indicative of enhanced methylation in the sample from the subject and cancer or a predisposition therefor.
3. The method according to claim 1 or claim 2 wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, colorectal cancer, pancreatic cancer, ovarian cancer and combinations thereof.
4. The method according to claim 1 or claim 2 wherein the sample comprises a body fluid or a derivative of a body fluid or a body secretion.
5. The method according to claim 4 wherein the body fluid is selected from the group consisting of whole blood, urine, saliva, breast milk, pleural fluid, sweat, tears and mixtures thereof.
6. A process for diagnosing a cancer, determining a prognosis for a subject suffering from a cancer or determining the efficacy of treatment of a cancer comprising:
(i) identifying and/or detecting enhanced methylation of a nucleic acid positioned within Chromosome 2 from about map position 2q14.1 to about map position 2q14.3 in a sample from a subject by performing a method comprising:
(a) treating the sample with an amount of a compound that selectively mutates a non-methylated cytosine residue under conditions sufficient to induce mutagenesis thereby producing a mutated nucleic acid;
(b) performing an amplification reaction with nucleic acid primers comprising a nucleotide sequence that is complementary to a sequence flanking or adjacent to a methylated cytosine residue or mutated residue at an equivalent position in non-methylated nucleic acid, wherein said methylated cytosine residue or said mutated residue is within a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32 and SEQ ID NO: 33; and
(c) identifying and/or detecting the temperature at which the amplified nucleic acid produced at (b) denatures, wherein the temperature at which the nucleic acid denatures is indicative of the presence of a methylated cytosine residue or a mutated residue and the level of methylation of said nucleic acid; and
(ii) comparing the level of methylation of the nucleic acid at (i) to the degree of methylation in a non-cancerous cell, wherein an enhanced level methylation in the nucleic acid at (i) compared to the level of methylation in the non-cancerous cell is indicative of enhanced methylation in the sample from the subject and cancer or a predisposition therefor.
7. A process for diagnosing a cancer, determining a prognosis for a subject suffering from a cancer or determining the efficacy of treatment of a cancer comprising:
(i) identifying and/or detecting enhanced methylation of a nucleic acid positioned within Chromosome 2 from about map position 2q14.1 to about map position 2q14.3 in a sample from a subject by performing a method comprising:
(a) treating said sample with an amount of a compound that selectively mutates a non-methylated cytosine residue under conditions sufficient to induce mutagenesis thereby producing a mutated nucleic acid;
(b) performing an amplification reaction with nucleic acid primers comprising a nucleotide sequence that is complementary to a sequence flanking or adjacent to a methylated cytosine residue or mutated residue at an equivalent position in non-methylated nucleic acid, wherein at least one of said probes or primers comprises a region that selectively hybridizes to an amplicon comprising a nucleotide sequence complementary to the mutated residue produced in the amplification reaction thereby forming a hairpin nucleic acid and preventing further amplification of said nucleic acid, and wherein said methylated cytosine residue or said mutated residue is within a nucleic acid comprising a nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32 and SEQ ID NO: 33; and
(c) identifying and/or detecting the amplified nucleic acid, wherein the detection of said amplified nucleic acid is indicative of the presence of a methylated cytosine residue or a mutated residue and the level of methylation of said nucleic acid; and
(ii) comparing the level of methylation of the nucleic acid at (i) to the level of methylation in a non-cancerous sample, wherein an enhanced level of methylation in the nucleic acid at (i) compared to the level of methylation in the non-cancerous sample is indicative of enhanced methylation in the sample from the subject and cancer or a predisposition therefor.
8. A process for diagnosing a cancer, determining a prognosis for a subject suffering from a cancer or determining the efficacy of treatment of a cancer comprising:
(i) identifying and/or detecting enhanced methylation of a nucleic acid positioned within Chromosome 2 from about map position 2q14.1 to about map position 2q14.3 in a sample from a subject by performing a method comprising:
(a) treating the sample with an amount of a compound that selectively mutates a non-methylated cytosine residue under conditions sufficient to induce mutagenesis thereby producing a mutated nucleic acid;
(b) performing an assay to determine a level of methylation of said nucleic acid, said assay comprising detecting one or more methylated cytosine residues within the nucleic acid and/or detecting one or more mutated residues at equivalent positions within the nucleic acid which is/are non-methylated, wherein the nucleic acid comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32 and SEQ ID NO: 33;
(ii) comparing the level of methylation of the nucleic acid at (i) to the level of methylation of the nucleic acid in a non-cancerous cell, wherein an enhanced level methylation in the nucleic acid at (i) compared to the level of methylation in the nucleic acid in the non-cancerous cell is indicative of enhanced methylation in the sample from the subject and cancer or a predisposition therefor.
9. The method according to any one of claims 1 , 2 or 6 to 8 , wherein the compound that selectively mutates a non-methylated cytosine residue is a metal salt of bisulphite.
10. The method according to any one of claims 6 to 8 , wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, colorectal cancer, pancreatic cancer, ovarian cancer and combinations thereof.
11. The method according to any one of claims 6 to 8 , wherein the sample comprises a body fluid or a derivative of a body fluid or a body secretion.
12. The method according to claim 11 , wherein the body fluid is selected from the group consisting of whole blood, urine, saliva, breast milk, pleural fluid, sweat, tears and mixtures thereof.